Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies

PURPOSE OF REVIEW: The therapeutic use of anti-PD-1/PD-L1 antibodies (nivolumab, pembrolizumab) is rapidly increasing. Given their mechanism of action that triggers T-cell activation, these immune checkpoint inhibitors induce specific adverse events that are mostly of immunologic origin. In this way... View More